玻璃体内注射bevacizumab 联合硅油填充治疗晚期糖尿病视网膜病变术后新生血管性青光眼
Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.
机构信息
Department of Ophthalmology, Iran University of Medical Sciences, Tehran, Iran.
出版信息
Eye (Lond). 2010 Apr;24(4):717-9. doi: 10.1038/eye.2009.94.
PURPOSE
To evaluate the effect of intra-silicone injection of bevacizumab for the treatment of neovascular glaucoma (NVG) after vitrectomy for advanced proliferative diabetic retinopathy.
METHODS
Bevacizumab was injected into the silicone oil in five pseudophakic eyes of five patients with NVG. The iris neovascularization (INV) and NVG had developed 1.5-4 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of INV, intraocular pressure and visual acuity.
RESULTS
In all eyes, INV regressed and intraocular pressure was controlled within 7 days. Visual acuity improved in all eyes. In one patient, INV and NVG recurred 10 weeks after the injection and was successfully treated with a repeat intra-silicone bevacizumab injection.
CONCLUSION
Intra-silicone injection of bevacizumab is effective in the treatment of patients with INV and NVG after vitrectomy for advanced proliferative diabetic retinopathy.
目的
评估玻璃体切除术后硅油内注射贝伐单抗治疗晚期增生性糖尿病视网膜病变继发新生血管性青光眼（NVG）的疗效。
方法
对 5 例 NVG 患者的 5 只术后硅油填充眼行硅油内注射贝伐单抗治疗。虹膜新生血管（INV）和 NVG 在玻璃体切除术后 1.5-4 个月发生。主要观察指标为 INV 消退、眼内压和视力。
结果
所有眼 INV 均消退，眼内压在 7 天内得到控制。所有眼视力均提高。1 例患者在注射后 10 周 INV 和 NVG 复发，再次行硅油内贝伐单抗注射治疗后成功。
结论
玻璃体切除术后硅油内注射贝伐单抗治疗晚期增生性糖尿病视网膜病变继发 INV 和 NVG 有效。
Zotero 插件